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Abstract
Signaling via the intracellular pathogen receptors nucleotide-binding
oligomerization domain-containing proteins NOD1 and NOD2
requires receptor interacting kinase 2 (RIPK2), an adaptor kinase that
can be targeted for the treatment of various inflammatory diseases.
However, the molecular mechanisms of how RIPK2 contributes to
NOD signaling are not completely understood. We generated FLAG-
tagged RIPK2 knock-in mice using CRISPR/Cas9 technology to study
NOD signaling mechanisms at the endogenous level. Using cells from
these mice, we were able to generate a detailed map of post-transla-
tional modifications on RIPK2. Similar to other reports, we did not
detect ubiquitination of RIPK2 lysine 209 during NOD2 signaling.
However, using site-directed mutagenesis we identified a new regu-
latory region on RIPK2, which dictates the crucial interaction with
the E3 ligase XIAP and downstream signaling outcomes.
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Introduction
Nucleotide-binding oligomerization domain-containing (NOD) pro-
teins NOD1 and NOD2 are intracellular pathogen recognition recep-
tors (PRRs) that sense the bacterial peptidoglycan (PGN) fragments
c-D-Glu-m diaminopimelic acid (DAP) and muramyl dipeptide
(MDP), respectively (Girardin et al, 2003a,b). NOD1 and NOD2
play an important role in the clearance of bacterial pathogens,
including Mycobacterium tuberculosis (Lee et al, 2016), Listeria
monocytogenes (Jeong et al, 2014), and multiple Chlamydiae
species (Zou et al, 2016). Aberrant NOD signaling has long been
associated with a range of inflammatory disorders (Caruso et al,
2014; Philpott et al, 2014), and recent findings suggest that inhibi-
tion of the NOD pathways could be beneficial in the treatment of
allergic asthma (Miller et al, 2018) and type 2 diabetes mellitus
(T2DM) (Amar et al, 2011; Schertzer et al, 2011; Denou et al, 2015;
Cavallari et al, 2017).
Binding of the respective ligands to NOD1 and NOD2 leads to
their self-oligomerization (Maharana et al, 2015) and the recruit-
ment of receptor-interacting serine/threonine-protein kinase 2
(RIPK2) via homotypic caspase recruitment domain (CARD)–CARD
interactions (Inohara et al, 2000). RIPK2 is the essential adaptor
kinase in the NOD signaling pathway and drives nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-jB) and mito-
gen-activated protein (MAP) kinase activation (Chin et al, 2002;
Park et al, 2007). The kinase activity of RIPK2 was initially reported
to be required for signal transduction and for critical autophospho-
rylation of RIPK2 on S176 in the activation loop of the kinase
domain (Dorsch et al, 2006) and Y474 in its CARD (Tigno-Aranjuez
et al, 2010). However, recent studies suggest that RIPK2 kinase
activity is dispensable for NF-jB activation and cytokine production
(Goncharov et al, 2018; Hrdinka et al, 2018). Furthermore, it has
been established that NOD signaling relies on ubiquitination of
RIPK2 (Tigno-Aranjuez et al, 2013). This process is coordinated by
multiple ubiquitin E3 ligases, including X-linked inhibitor of apopto-
sis protein (XIAP) (Krieg et al, 2009; Damgaard et al, 2012; Heim
et al, 2019). XIAP binds to the kinase domain of RIPK2 via its bac-
ulovirus IAP repeat 2 (BIR2) domain (Krieg et al, 2009; Bertrand
et al, 2011; Nachbur et al, 2015) and generates K63-linked polyubiq-
uitin chains on multiple lysine residues (Goncharov et al, 2018).
This leads to the recruitment of the linear ubiquitin chain assembly
complex (LUBAC) (Damgaard et al, 2012) and the generation of M1-
linked polyubiquitin chains on RIPK2 that serve as binding plat-
forms for IjB kinase (IKK) and transforming growth factor beta-acti-
vated kinase 1 (TAK1) complexes.
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While the importance of XIAP and LUBAC for immune responses
mediated by NOD1 and NOD2 has been demonstrated in vitro and
in vivo, not much is known about the function of individual ubiquiti-
nation sites on RIPK2. A putatively ubiquitinated lysine residue on
RIPK2 (K209) was discovered more than 10 years ago in a systematic
screening of lysine to arginine mutations (K/R) that disrupted NF-jB
activation in overexpression experiments (Hasegawa et al, 2008). A
subsequent study showed that the K209R mutation blocked RIPK2
ubiquitination and signaling (Tigno-Aranjuez et al, 2013), and it was
concluded that K209 is directly ubiquitinated and is indispensable for
NOD2 responses. Nevertheless, ubiquitination of RIPK2 on K209 has
not been demonstrated experimentally. Intriguingly, a recently pub-
lished proteomics experiment reported multiple ubiquitination sites
on RIPK2, but the authors did not identify K209 (Goncharov et al,
2018). Instead, they found ubiquitination sites on the C terminus of
RIPK2 and generated a K410R/K538R double mutation that reduced
MDP-dependent responses of THP-1 cells. Altogether, this highlights
that our understanding of how post-translational modifications
(PTMs) of RIPK2 regulate NOD signaling is incomplete.
Due to the association with inflammatory diseases, pharmaceuti-
cal companies have invested in the development of inhibitors for
the NOD signaling pathway. RIPK2 has been established as a poten-
tial drug target, particularly in inflammatory bowel disease, and
RIPK2-targeting kinase inhibitors have been developed (Damgaard
et al, 2012; Tigno-Aranjuez et al, 2014; Nachbur et al, 2015). Recent
studies showed that the inhibition of NOD signaling is not directly
due to the inhibition of the kinase function of RIPK2, but rather by
the disruption of the RIPK2-XIAP interaction (Nachbur et al, 2015;
Goncharov et al, 2018; Hrdinka et al, 2018). This has led to the
hypothesis that protein–protein interaction inhibitors could be used
to treat NOD-driven diseases and highlights the need for a detailed
understanding of post-translational modifications on RIPK2.
A significant issue that has hindered our understanding of such
mechanisms of the NOD signaling pathway is the lack of specific bio-
chemical tools. Most studies have been limited to overexpression
experiments in cancer cell lines, which has many drawbacks includ-
ing the formation of artefactual interactions or altered protein activi-
ties (von Mering et al, 2002; Aebersold & Mann, 2003). In the context
of NOD signaling, it was shown that ectopic overexpression of NOD
receptor complex components leads to pathway activation indepen-
dent of PGN binding (McCarthy et al, 1998; Thome et al, 1998; Ogura
et al, 2001). To study NOD2 signaling mechanisms and investigate
the molecular determinants of RIPK2 activation, we established a new
mouse strain with endogenously FLAG-tagged RIPK2. This allowed us
to isolate RIPK2 from primary tissues and cells and to characterize the
PTMs on RIPK2 that occur during MDP-induced signaling at endoge-
nous levels. While we did not identify ubiquitination of the putative
ubiquitination site K209, we identified a novel regulatory region that
controls XIAP binding and is required for signal transduction.
Results and Discussion
FLAG-RIPK2 knock-in mice represent a novel tool to study
endogenous NOD signaling mechanisms
To study NOD signaling at the endogenous level and to investigate
how RIPK2 regulates signal transduction, we generated N-terminally
FLAG-tagged RIPK2 knock-in mice by microinjection of single guide
RNAs (sgRNAs), recombinant Cas9 protein, and a dsDNA oligonu-
cleotide encoding the FLAG-tagged sequence of RIPK2 with homolo-
gous arms upstream and downstream of the sgRNA targeted region
into wild-type C57Bl/6 embryos (Fig EV1). Using this process, we
generated mice harboring the desired FLAG-tagged version of
RIPK2, as well as mice with defined insertions and deletions. After
backcrossing to C57Bl/6 mice, we established a FLAG-RIPK2 knock-
in mouse strain as well as a new RIPK2 knockout strain.
First, we explored the tissue distribution of RIPK2 by testing
homogenates from organs of FLAG-RIPK2 and wild-type mice by
Western blot. As the expression levels of RIPK2 in these organs
were too low for detection using anti-FLAG antibodies, we subjected
organ homogenates to anti-FLAG immunoprecipitation (Fig 1A) and
probed the supernatants from boiled beads for the presence of
RIPK2. We found high levels of FLAG-RIPK2 in homogenates from
the lung and the spleen, and lower amounts in the brain, colon,
small intestine, skin, and liver. We did not detect FLAG-RIPK2 in
the kidney.
We then tested the functionality of FLAG-RIPK2 using IFNc-
primed bone marrow-derived macrophages (BMDMs). Priming with
IFNc is required for the BMDMs to take up and respond to MDP
(Fekete et al, 2017). Upon MDP stimulation, cells generated from
homozygous (KI/KI) or heterozygous (WT/KI) FLAG-RIPK2 mice
induced NF-jB and MAP kinase pathways equivalent to wild-type
cells (Fig 1B). Western blot for RIPK2 also revealed even expression
levels between wild-type and FLAG-tagged versions of RIPK2, which
was particularly clear in the heterozygote samples (Fig 1B). After
stimulation with MDP, ubiquitination of FLAG-RIPK2 in BMDMs
from knock-in mice was comparable to ubiquitination of RIPK2 in
cells from wild-type mice (Fig EV2). As expected, cells generated
from our new strain of RIPK2 knockout mice were unresponsive to
MDP and did not express detectable RIPK2. Cytokine production of
BMDMs after MDP stimulation was then measured by ELISA
(Fig 1C). In IFNc-primed wild-type and FLAG-RIPK2 BMDMs, treat-
ment of MDP induced the secretion of TNF, IL-6, and MCP-1 at
equal levels, while RIPK2 KO BMDMs were unresponsive. To con-
firm that NOD2-dependent responses in FLAG-RIPK2 mice were
indistinguishable from wild-type mice in vivo, we intraperitoneally
(i.p.) injected MDP or PBS into wild-type, FLAG-RIPK2 and RIPK2
knockout mice and measured cytokine levels in the serum by ELISA
(Fig 1D). MDP challenge caused a reproducible increase in the
levels of IL-6 and TNF in the serum of wild-type and knock-in mice.
In RIPK2 deficient mice, MDP injection did not result in an increase
of cytokines. Altogether these data show that FLAG-RIPK2 mice
and primary cells from these mice responded normally to NOD2
stimulation.
Post-translational modifications on RIPK2
Initially, it was thought that the kinase activity of RIPK2 was
required for signaling down stream of NOD receptors (Nembrini
et al, 2009). Recently, however, two groups independently showed
that it is dispensable for NOD mediated NF-jB activation and cyto-
kine production (Goncharov et al, 2018; Hrdinka et al, 2018),
although it is an open question whether the kinase activity is impor-
tant in other RIPK2-regulated cellular processes, such as autophagy
(Cooney et al, 2010; Homer et al, 2010; Anand et al, 2011; Lupfer
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et al, 2013). These studies indicate that it is rather post-translational
modification, particularly ubiquitination of the adaptor protein
RIPK2, that is the critical mediator of NOD/RIPK2 signaling.
Although it has been demonstrated that RIPK2 is post-translationally
modified during signaling, we did not observe ubiquitination of
RIPK2, as characterized by a high molecular weight smear on
Western blots, in whole-cell lysates of MDP-stimulated BMDMs
(Fig 1B). We also did not observe ubiquitination sites on RIPK2
when we performed anti-FLAG immunoprecipitation on MDP-stimu-
lated FLAG-RIPK2 BMDMs followed by mass spectrometry analysis
(Dataset EV1). These data indicate that the majority of cellular
RIPK2 is not ubiquitinated and not part of the NOD signaling com-
plex, even after stimulation, and suggests that an additional purifi-
cation step is required to investigate RIPK2 in its activated state.
Therefore, we established a sequential pulldown protocol to
enrich for the RIPK2 pool that participates in NOD2 signaling
complexes. IFNc-primed BMDMs were stimulated with MDP for
30 min and lysates were first enriched for ubiquitinated proteins
using glutathione S-transferase (GST)-ubiquitin associated domain
(UBA) bound to Sepharose beads (Hjerpe et al, 2009; Fiil et al,
2013). Bound proteins were then eluted with Glutathione, and elu-
ates were subjected to anti-FLAG immunoprecipitation, followed by
elution with 3x-FLAG peptide (Fig 2A). The first pulldown (UBA,
lane B) yielded a sample containing readily detectable levels of a
ladder of RIPK2 species suggestive of ubiquitination, as well as
many other ubiquitinated proteins (anti-ubiquitin, bottom panel).
The sample obtained by sequential pulldown with anti-FLAG (lane
C) also contained modified RIPK2; however, the background of
ubiquitinated proteins was significantly reduced, further suggesting
that this approach resulted in purification of activated RIPK2.
Tryptic digests of these samples were then generated and ana-
lyzed by mass spectrometry, revealing a substantial enrichment of
ubiquitin and RIPK2 peptides. To specifically determine stimulation-
dependent PTMs on RIPK2, this dataset was compared with datasets
obtained from FLAG pulldowns of unstimulated BMDMs. In unstim-
ulated BMDMs, only one single K-ɛ-diglycine site (diGly, diglycine
remnant on lysine after tryptic digestion of ubiquitinated proteins)
on RIPK2 was observed at the C-terminal end of the kinase domain
(K310). In contrast, MDP-stimulated BMDMs revealed multiple
RIPK2 ubiquitination sites within the kinase domain (K182, K203),
in the intermediate region (K326, K369) and in the CARD (K527,
K537) (Fig 2B). The function of most of the detected sites is still
uncharacterized; only one recent study showed that human THP-1




Figure 1. Flag-RIPK2 knock-in mice as a tool to study endogenous NOD signaling mechanisms.
A Tissue distribution of RIPK2 determined by anti-FLAG immunoprecipitation. Organ homogenates from WT (wild-type) and KI (homozygous FLAG-RIPK2) mice were
subjected to anti-FLAG immunoprecipitation and immunoblotting.
B Inflammatory signaling in wild-type (WT/WT), RIPK2 CRISPR KO (KO/KO), and FLAG-RIPK2 heterozygous (WT/KI) and homozygous (KI/KI) BMDMs. BMDMs were primed
with IFNc, stimulated with MDP for indicated times, and analyzed by immunoblotting.
C Cytokine production of RIPK2 CRISPR KO (KO), wild-type (WT), and FLAG-RIPK2 heterozygous (WT/KI) and homozygous (KI/KI) BMDMs in response to MDP. BMDMs
were left untreated or treated with IFNc alone or IFNc and MDP overnight and cytokines were measured by ELISA. N = 5–8 mice. Shown is average  SEM.
nsP > 0.05; **P ≤ 0.01; ****P ≤ 0.0001; two-way ANOVA.
D Serum cytokines in RIPK2 CRISPR KO (KO), wild-type (WT), and FLAG-RIPK2 heterozygous (WT/KI) or homozygous (KI/KI) mice after i.p. MDP administration. Mice were
injected i.p. with PBS or MDP, sacrificed after 4 h and serum cytokines were measured by ELISA. N = 3–6 mice. Shown is average  SEM. nsP > 0.05; **P ≤ 0.01;
two-way ANOVA.
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corresponds to K537 in mice) display reduced NF-jB activation and
cytokine production. We were not able to detect the previously
described ubiquitination site K209 (Hasegawa et al, 2008) using our
stringent protocol.
Phosphopeptides on RIPK2 were detected in both unstimulated
and MDP-stimulated BMDMs. Stimulation-dependent phosphoryla-
tion was detected in the intermediate region (T320, S362, S373) and
the CARD (S539). The activation loop of RIPK2 was phosphorylated
on two residues (S176, S178); however, these phosphopeptides
were discovered in stimulated as well as in unstimulated cells. This
was surprising since phosphorylation of the kinase activation loop
is associated with RIPK2 activation (Dorsch et al, 2006; Rahman
et al, 2014).
To further confirm the physiological importance of the RIPK2
ubiquitination sites, we examined the ubiquinome of the human
monocytic cell line THP-1 employing diGly proteomics. In unstimu-
lated cells, we did not detect any diGly sites on RIPK2 but we consis-
tently observed several diGly marks after L18-MDP stimulation
(Fig 2C, Dataset EV2). The sites identified in THP-1 cells reflected
our results obtained using the sequential pulldown protocol in
mouse cells, validating our initial approach. All stimulation-depen-
dent diGly modifications that we detected on murine RIPK2 residues,
which are also conserved in humans, were detected in L18-MDP-
stimulated THP-1 cells (K182, K203, K326, K538). Additionally, two
diGly-modified lysines (K376, K410) that are not conserved in mice
were found. Again, with this second protocol using human cells, we
were not able to detect ubiquitination of K209. As expected, we did
not detect any phosphorylation events on RIPK2 using this approach,
indicating that there are no simultaneous ubiquitination and phos-
phorylation events on a single peptide after tryptic digest.
Most PTMs on RIPK2 are redundant for NOD2 signaling
While multiple ubiquitin E3 ligases and deubiquitinases (DUBs)
have been suggested to regulate RIPK2 ubiquitination, the contribu-
tion of individual ubiquitination sites on RIPK2 has not been charac-
terized in endogenous systems so far. Here, we demonstrated that
RIPK2 is ubiquitinated on multiple lysine residues. This is not
unusual as many proteins become ubiquitinated on multiple sites
during signaling (Ball et al, 2016; Wagner et al, 2016). Typically,
there appears to be flexibility in the lysine residues that can be ubiq-
uitinated and often mutation of a single lysine has little impact on
signaling. This is believed to be because E3 ligases are not usually
restricted to a specific motif, in the way that for example kinases or
caspases are, and can therefore be promiscuous in the lysine that
they modify (Petroski & Deshaies, 2003; Wu et al, 2003).
To assess the impact of individual RIPK2 PTMs on NOD signal-
ing, we generated mutants of lysine and serine residues that we
found to be modified upon NOD2 stimulation and are highly con-
served among mammals (Fig 2D). Additionally, we included con-
served sites that have previously been associated with RIPK2
activation (Fig 2D; Dorsch et al, 2006; Hasegawa et al, 2008; Tigno-
Aranjuez et al, 2010). These corresponded to K182, K203, K326,




Figure 2. Identification of RIPK2 PTMs during NOD signaling by mass spectrometry.
A Two-step enrichment to isolate ubiquitinated RIPK2 from BMDMs. Protein lysates from FLAG-RIPK2 BMDMs (A) were sequentially subjected to ubiquitin enrichment
(UBA, B) and FLAG pulldown (C) prior to protein elution and subsequent mass spectrometry analysis.
B Schematic representation of RIPK2 PTMs detected in MDP-stimulated vs. unstimulated BMDMs. Red: phosphorylation, green: ubiquitination. N = 3 experiments.
C DiGly modifications on RIPK2 in L18-MDP-stimulated vs. L18-MDP-unstimulated THP-1 cells determined by diGly proteomics. Shown are P values and log2 differences
of modified peptides based on imputed values; t-test. Score: peptide identification score as determined by MaxQuant.
D Sequence conservation of stimulation-dependent modified serine (red) and lysine (green) residues among mammals. The degree of conservation is indicated by color
saturation.
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We used these RIPK2 variants to test whether single ubiquitina-
tion and phosphorylation sites on RIPK2 are critical for its function
in a close-to-endogenous setting. For this, we generated RIPK2-defi-
cient THP-1 cells by transient transfection with Cas9 and RIPK2
sgRNA encoding plasmids and confirmed the knockout of RIPK2 by
Western blot. These knockout cells were then transduced with doxy-
cycline-inducible RIPK2 constructs to express RIPK2 at levels similar
to wild-type THP-1. In contrast to overexpression studies, expression
of RIPK2 alone did not autoactivate NF-jB, but additional treatment
with L18-MDP-induced transient phosphorylation of p65 and IjBa
and degradation of IjBa (Fig 3A). Upon MDP stimulation, cells
reconstituted with all mutant forms of RIPK2 activated NOD signal-
ing normally, except the previously described K209R mutant.
After L18-MDP stimulation, we observed significantly reduced
levels of IL-8 in RIPK2-deficient cells reconstituted with the K209R
mutant, while all other mutants produced equal amounts of IL-8
compared with either wild-type THP-1 cells or RIPK2-deficient cells
reconstituted with wild-type RIPK2 (Fig 3B).
Notably, RIPK2 K209R was the only form of RIPK2 which
seemed to present in a second, higher molecular weight band after
stimulation, similar to recently described Riposomes (Ellwanger
et al, 2019). To test the impact of each individual modified site on
the ubiquitination pattern on RIPK2 during NOD signaling, cells
were subjected to UBA pulldowns and analyzed by Western blot.
Stimulation with L18-MDP led to distinct RIPK2 polyubiquitination
(Fig 3C) and the removal of single ubiquitination or phosphoryla-
tion sites, besides K209, did not affect RIPK2 ubiquitination.
It was previously reported that K209 is critical for RIPK2 ubiquiti-
nation and NOD signaling (Hasegawa et al, 2008). However, we
observed that residual ubiquitination of RIPK2 K209R was still pre-
sent. Since RIPK2 K209R failed to activate NF-jB and to produce
cytokines, and displayed reduced ubiquitination, we hypothesized
that this mutation led to a loss of the critical K63- or M1-linked ubiq-
uitin chains. To test this hypothesis, cells reconstituted with wild-
type RIPK2 or K209R RIPK2 were stimulated with L18-MDP and sub-
jected to either UBA pulldown or to pulldowns with K63- or M1-
chain-specific antibodies (Newton et al, 2008; Matsumoto et al,
2012). Compared to wild-type RIPK2, the ubiquitination of K209R
was reduced in all pulldowns; however, K63- and M1-linked chains
were still detected, indicating that the K209R mutant is still able to
be ubiquitinated on other lysine residues (Fig 3D). These reduced
chains are, however, unable to induce downstream signaling which
might explain the lack of global ubiquitination events after MDP
stimulation in cells harboring the K209R mutation (Panda & Gekara,
2018).
Our results clearly indicate that most single phosphorylation and
ubiquitination events on RIPK2 are redundant. While this is the case
for many signaling proteins, there are some exceptions to this gen-
eral rule. For example, mutation of K377 in RIPK1 has a profound
effect on RIPK1 ubiquitination and TNFR1 induced activation of NF-
jB (O’Donnell et al, 2007). Our data as well as previous studies
could lead to the assumption that K209 is another similarly special
residue because the K209R mutation blocked overexpression-
induced NF-jB activation and RIPK2 ubiquitination (Hasegawa
A
B C D
Figure 3. Characterization of RIPK2 diGly- and phosphosite mutations.
A Activation of the NF-jB pathway by RIPK2 Lysine- and phosphosite mutants. RIPK2-deficient THP-1 cells reconstituted with wild-type RIPK2 or RIPK2 mutants were
stimulated with L18-MDP, harvested at indicated time points and activation of the NF-jB pathway was analyzed by immunoblotting.
B IL-8 production of wild-type THP-1 and RIPK2-deficient THP-1 cells reconstituted with wild-type RIPK2 or RIPK2 mutants and stimulated with L18-MDP was assessed
by ELISA. N = 4–8 experiments. Shown is average  SEM. *P ≤ 0.05; two-way ANOVA.
C RIPK2 ubiquitination determined by UBA pulldown in RIPK2-deficient cells reconstituted with wild-type or mutant RIPK2 after stimulation with L18-MDP.
D Detection of K63- and M1-linked ubiquitin chains by UBA pulldown or pulldown with ubiquitin chain type-specific antibodies in RIPK2-deficient cells reconstituted
with wild-type or K209R RIPK2 after stimulation with L18-MDP.
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et al, 2008) and the mutant has a loss of function phenotype when
overexpressed together with ubiquitin in HEK 293T cells (Tigno-
Aranjuez et al, 2013). However, unlike K377 in RIPK1, K209 is on
the C-lobe of the kinase domain of RIPK2, which is already indica-
tive of a different function of this site.
K209 and I212 form a regulatory region that influences
signal transduction
Since neither we nor others were able to detect ubiquitination of
K209 by mass spectrometry analysis (Goncharov et al, 2018), and
mutation of K209 reduced, but did not completely abolish K63 and
M1 linked ubiquitination of RIPK2 yet this same mutation stopped
NF-jB activation and cytokine production, we hypothesized that
K209 is not a critical ubiquitination site but serves a different func-
tion. K209 is located at the N-terminal end of aE helix in the C-lobe
of the kinase domain (Fig 4A; PDB 4C8B; (Canning et al, 2015)). It
is part of a hydrophobic pocket formed by amino acids of helix aE
and amino acids in the loop between helix aE and aEF, which are
suggestive of a regulatory interface. To test the hypothesis that dis-
ruption of this region prevents NOD2 signaling, we generated muta-
tions of amino acids K209 and I208 that contribute to the making of
this pocket. While K209 is invariant among vertebrates, I208 is
replaced by valine in most vertebrate RIPK2 sequences (Fig 4B). We
also mutated I212, which is part of the aE helix with its side chain
sitting deep within the pocket. I212 is highly conserved and only
replaced by other hydrophobic amino acids, such as valine or
methionine, in some vertebrate species.
We reconstituted RIPK2-deficient THP-1 cells with the new RIPK2
mutants we generated and tested them for NF-jB activation, RIPK2
ubiquitination, and cytokine secretion. The expression levels of
these RIPK2 mutants seemed equivalent (Fig 4C). Conservative
I208V and I212M mutations did not prevent activation of NF-jB or
the production of IL-8 after MDP stimulation (Fig 4D). In contrast,
cells that expressed the RIPK2 I212A mutant produced significantly
more IL-8 than cells expressing wild-type RIPK2, and markers of
NF-jB activation were similar or enhanced (Fig 4C and E). We also
observed enhanced ubiquitination after MDP stimulation of RIPK2
I212A compared with wild-type or other mutant forms of RIPK2
(Fig 4E). Finally, the substitution of isoleucine 212 with an aspartic
acid (I212D) completely blocked RIPK2 ubiquitination and NF-jB
activation. These results suggest that the C-lobe pocket is critical in
the regulation of RIPK2 activity and may act to recruit an E3 ligase,






Figure 4. Functional studies of RIPK2 mutations introduced in close proximity to K209R.
A Structural features of the RIPK2 kinase domain (left) and location of K209 within a hydrophobic pocket between helices aEF and aE (right). Shown is chain B of the
RIPK2 kinase in complex with ponatinib from PDB:4C8B. The electrostatic interaction potential is shown as a blue to red gradient.
B Conservation of amino acids creating a hydrophobic pocket between helices aEF and aE. Degree of conservation among 227 vertebrate species indicated by
background color saturation.
C Activation of the NF-jB pathway by RIPK2 pocket mutants. RIPK2-deficient THP-1 cells were reconstituted with wild-type RIPK2 or RIPK2 mutants, stimulated with
L18-MDP, harvested at indicated time points, and analyzed by immunoblotting.
D IL-8 production of RIPK2-deficient THP-1 cells reconstituted with wild-type RIPK2 or RIPK2 mutants and stimulated with L18-MDP was assessed by ELISA.
N = 3–8 experiments. Shown is average  SEM. nsP > 0.05; *P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001; two-way ANOVA.
E Ubiquitination of RIPK2 pocket mutants. RIPK2-deficient THP-1 cells were reconstituted with wild-type or mutant RIPK2, left unstimulated or stimulated with
L18-MDP and subjected to UBA pulldown and immunoblotting.
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While these data confirm previous reports that K209 is indispens-
able for NOD mediated NF-jB activation and cytokine production,
and that RIPK2 ubiquitination is impaired when K209 is mutated to
an arginine, the absence of direct ubiquitination of K209 indicated a
different mechanism than previously reported. The reason for this is
twofold: Firstly, we used two multi-replicate complementary experi-
mental approaches to determine the phosphorylation- and ubiquiti-
nation signature on RIPK2 upon activation. The fact that we
identified identical diGly sites on RIPK2 in mouse (BMDMs) and in
human (THP-1) gives high confidence in our datasets. Despite the
consistency of the PTM data across the two cell lines, we, like others
in the field, failed to observe a diGly site corresponding to K209.
Secondly, mutation of a residue in close proximity, but not directly
affecting K209, resulted in an even more dramatic impact on RIPK2
ubiquitination than mutation of K209 itself. This suggests that struc-
tural integrity of this region is critical for signal transduction. To this
end, we cannot exclude that our I212D mutation rendered K209
inaccessible for ubiquitination, but further studies will be required
to examine this experimentally.
It should be noted that we not only failed to detect ubiquitinated
K209, but we also did not detect unmodified K209 in our datasets
on MDP-stimulated BMDMs or THP-1 cells. Nevertheless, when ana-
lyzing other datasets that identified RIPK2 in deep proteome and
pan-kinome experiments (utilizing broad specificity kinase inhibi-
tors to enrich for kinases), this region was readily identifiable as an
unmodified tryptic peptide (Creixell et al, 2015; Ruprecht et al,
2015; Slany et al, 2016; Klaeger et al, 2017). This could be because
we specifically enriched for activated RIPK2 in our protocols and we
did not use kinase inhibitors in our approaches. We therefore can-
not definitively refute the idea of K209 ubiquitination, although the
current evidence suggests that there may be as-yet other unidenti-
fied post-translational modifications hindering its identification.
Lastly, the fact that a third method did not lead to the detection of a
diGly site on RIPK2 K209 (Goncharov et al, 2018) hints to the direc-
tion that this particular portion of RIPK2 is more complex than cur-
rently understood.
Mutation of K209 and I212 disrupts XIAP binding
An alternative explanation for the loss of the potential to activate
NF-jB and cytokine production of the K209R and I212D mutations
is instability due to misfolding or impairment of the dimerization
potential. The equivalent expression levels of the RIPK2 mutants
suggested that the structural integrity of RIPK2 was not overtly com-
promised. However, to exclude a trivial explanation for the com-
plete lack of signaling of the I212D mutant in particular, and more
rigorously show that the mutants retained their structural integrity,
we devised an intracellular thermal stability test (Fig 5A) based on
reports that kinase inhibitors can increase the thermal stability of
their targeted kinases (Martinez Molina et al, 2013; Jafari et al,
2014; Alshareef et al, 2016; Martinez Molina & Nordlund, 2016;
Seashore-Ludlow et al, 2018). We modified this assay to examine
the effects of mutation on protein stability as a marker for structural
integrity, and we think that it could be more widely used to deter-
mine whether a particular mutation affects structural integrity in a
semi-quantitative manner.
At the physiological temperature of 37°C, wild-type RIPK2 and
all RIPK2 mutants were expressed at equal levels. With increased
temperature, all mutants displayed similar stability compared with
wild-type RIPK2. In particular, all I212 mutants, I212A (activating),
I212M (residue in Damselfish), and I212D (inactivating) had an
almost identical thermal stability profile, strongly suggesting that
the mutations of this pocket had not caused major structural disrup-
tion. To estimate the effects of these mutations on the structural
integrity of RIPK2, we employed molecular modeling using the
DynaMut software (Rodrigues et al, 2018). This software predicted
that all the mutants increase rigidity of the aG region, the activation
loop, and a portion of the N-lobe aC helix with K209R(1.411 kcal/
mol) > I212A(0.764 kcal/mol) > I212D(0.38 kcal/mol) (Fig EV3).
Since this increased rigidity is predicted for both activating (I212A)
and inactivating (K209R, I212D) mutations, it is unlikely to be the
cause of the loss of function.
The ubiquitin E3 ligase XIAP is indispensable for NOD2
responses in vitro and in vivo (Bauler et al, 2008; Krieg et al, 2009;
Damgaard et al, 2012; Stafford et al, 2018) and binds to the RIPK2
kinase domain via its Baculovirus IAP Repeat 2 (BIR2) domain
(Krieg et al, 2009; Damgaard et al, 2012). The structural determi-
nants underlying the interaction between the two proteins remain
unclear. The XIAP-BIR2 domain contains a deep and distinctive
hydrophobic cleft that typically mediates binding to proteins harbor-
ing an IAP-binding motif (IBM) as present in caspases or second
mitochondria-derived activator of caspases (SMAC) (Wu et al, 2000;
Verhagen et al, 2007). However, RIPK2 does not contain such a
motif. It is possible that XIAP binds to RIPK2 in a non-canonical
fashion, independently of an IBM. Such a mechanism has been
shown with the caspase Dronc and the XIAP homolog DIAP1 in
A B
Figure 5. RIPK2 K209 and I212 mediate XIAP binding.
A Thermal stability assay using selected RIPK2 mutants. THP-1 cells expressing RIPK2 were subjected to heat treatment, and non-denatured fractions were analyzed by
immunoblotting.
B Binding of RIPK2 to XIAP-BIR2. Lysates from RIPK2-deficient THP-1 cells reconstituted with WT or mutant RIPK2 were subjected to pulldown experiments with
recombinantly expressed XIAP-BIR2 and analyzed by immunoblotting.
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Drosophila melanogaster. Binding of Dronc to DIAP1 is mediated via
a short 12-residue peptide located between the CARD and the pro-
tease domain of Dronc that binds into the hydrophobic cleft of the
DIAP in a similar fashion as observed in IBM-containing proteins.
Therefore, one explanation could be that the RIPK2-XIAP interaction
occurs in a similar, non-canonical fashion; however, the region
around K209 and I212 has the shape of a pocket. The binding mode
of RIPK2 and XIAP-BIR2, therefore, would be completely different
from the previously observed interactions. Alternatively, XIAP could
bind somewhere else, and mutation of K209 and I212 might lead to
conformational changes that have an impact on the structure or ori-
entation of the interaction interface. A region in the N-lobe of
RIPK2, in particular residues R36 and R41, was identified as a criti-
cal interaction region for the BIR2 of XIAP (Hrdinka et al, 2018).
However in all reported crystal structures, the RIPK2 kinase domain
is organized in head-to-tail dimers (PDB: 4C8B, 5AR4, 6ES0, 6FU5,
5J79) and the regions around R36 and R41 are quite far apart from
K209 (approximately 40 Å). According to these structures, it is unli-
kely that the BIR2 of XIAP binds both areas simultaneously, but the
reason for reduced binding of the K209R and I212D mutant could be
due to conformational impairment or that it may have influenced
binding to XIAP indirectly.
To test whether mutation of K209 and I212 disrupted XIAP bind-
ing, a purified, recombinant, GST-coupled BIR2 domain of XIAP was
used to precipitate RIPK2 from THP-1 lysates (Fig 5B). Wild-type
RIPK2 was strongly enriched by XIAP-BIR2 pulldown, and I212A
was even more abundant, correlating with the increased stimulus-
dependent ubiquitination of this mutant and increased cytokine
secretion compared with wild-type RIPK2. Binding of K209R and
I212D to the BIR2 of XIAP was, however, drastically reduced and
comparable to R41L, a RIPK2 mutant previously shown to have
impaired binding to XIAP (Hrdinka et al, 2018).
In recent studies, higher order intracellular signaling platforms
consisting of RIPK2 and NOD receptors were described (Gong et al,
2018; Pellegrini et al, 2018; Ellwanger et al, 2019). In particular,
inhibition of XIAP by either siRNA or by SMAC mimetic com-
pounds led to RIPK2-containing speck-like structures in cells, ter-
med Riposomes (Ellwanger et al, 2019). Here, we described two
mutations that perturbed the interaction between RIPK2 and XIAP.
On close examination, RIPK2 K209R seems to accumulate in a
higher order band in a Western blot after stimulation (Fig 3A),
consistent with the hypothesis that in the absence of XIAP, RIPK2
is moved to Triton-insoluble Riposomes. However, the RIPK2
I212D or the RIPK2 R41L mutations, which reduce RIPK2-XIAP
interaction to a similar level to the RIPK2 K209R mutation, did not
lead to an equivalent band in Western blots after stimulation.
Therefore, these new XIAP binding mutants will provide novel
insight into the mechanism and function of Riposome formation
and their relevance for NOD signaling.
Taken together, our work provides a detailed and systematic
map of post-translational modifications on RIPK2 during NOD sig-
naling, and we provide evidence that most single phosphorylation
and ubiquitination events on RIPK2 are redundant in systems with
close-to-endogenous levels of RIPK2. We identified a regulatory
region on RIPK2 which influences the crucial interaction with XIAP.
This region includes a pocket-shaped region around residues I212
and K209 on the C-lobe of RIPK2’s kinase domain. Our findings give
an explanation to the conundrum that has plagued the field to date:
why mutations of K209 reduce RIPK2 ubiquitination and block NOD
signaling, yet ubiquitination of K209 has never been detected experi-
mentally. As interfering with the RIPK2-XIAP interaction has
emerged as a strategy to inhibit NOD signaling, it is tempting to
speculate that this region could be targeted with small molecules for
the treatment of diseases with increased NOD signaling. Although
we cannot conclusively demonstrate that mutations in the region of
this pocket do not disrupt RIPK2 in a manner which may be impor-
tant for its function (kinase activity, autophagy, dimerization), our
data collectively suggest that site-directed mutagenesis of either
K209 or I212 blocks RIPK2 ubiquitination and inflammatory signal-
ing by displacing XIAP.
Materials and Methods
Generation of FLAG-RIPK2 CRISPR knock-in mice
The FLAG-RIPK2 mice were generated by the MAGEC laboratory
(WEHI) as previously described (Kueh et al, 2017) on a C57BL/6J
background. To generate FLAG-RIPK2 mice, 20 ng/ll of Cas9
mRNA, 10 ng/ll of sgRNA (TGAACGGGGACGCCATCTGC;) and




into the cytoplasm of fertilized one-cell stage embryos. Twenty-four
hours later, two-cell stage embryos were transferred into the oviducts
of pseudo-pregnant female mice. Viable offspring were genotyped by
next-generation sequencing.
Cell culture, generation of BMDMs, and stimulation protocols
Wild-type THP-1 cells and 293T cells were sourced from ATCCTM.
THP-1 cells were cultured in RPMI supplemented with 8% FBS and
antibiotics (penicillin, streptomycin, GIBCO) at 37°C with 10% CO2
in a humidified incubator. 293T cells were cultured in DMEM
(GIBCO) with 8% FBS in the same conditions. BMDMs were gener-
ated from the femur and tibiae of mice and cultured for 6 days in
DMEM (InvivoGen) supplemented with 8% FBS (GIBCO) and 20%
L929 supernatant and antibiotics (penicillin, streptomycin). Cells
were then detached using trypsin-EDTA and replated in 12- and 24-
well tissue culture plates. Replated cultures of BMDMs were primed
with murine interferon-c (5 ng/ml, R&D Systems) overnight and
again 2 h before stimulation with MDP (10 lg/ml, InvivoGen).
THP-1 cells were stimulated with L18-MDP (200 ng/ml, Bachem).
Generation of RIPK2 CRISPR knockout THP-1 cells
RIPK2-deficient THP-1 cells were generated using a CRISPR/Cas9-
based knockout workflow as previously described (Schmid-Burgk
et al, 2014). Briefly, a sgRNA (GACCTGCGCTACCTGAGCCGCGG)
targeting RIPK2 was designed. THP-1 cells were nucleofected with
one plasmid expressing sgRNA and one expressing mCherry-Cas9
(pLK0.1- gRNA-CMV-GFP, CMV-mCherry-Cas9) using the SG Cell
Line 4D-NucleofectorTM X Kit S and a 4D-Nucleofector X unit.
mCherry-positive cells were sorted and cloned by limiting dilution.
After identifying clones, cells were replated and grown to identify
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RIPK2 knockout clones by assessing RIPK2 expression on Western
blot.
Intraperitoneal MDP injections
All in vivo experiments were performed according to the guidelines
of the animal ethics committee of WEHI, ethics approval (2011.014,
2014.004 and 2017.004). Sex- and age-matched littermate controls
were used within each experiment. For in vivo MDP challenge: wild-
type, RIPK2 knockout, and FLAG-RIPK2 knock-in (hetero- and
homozygous) mice were administered MDP (5 mg/kg, i.p. in 200 ll
PBS, Bachem) or PBS and sacrificed after 4 h. Peripheral blood was
collected by cardiac puncture.
Western blotting
Following stimulation, cells were lysed in 2 × SDS lysis buffer
(126 mM Tris–HCl pH 8, 20% v/v glycerol, 4% w/v SDS, 0.02% w/
v Bromophenolblue, 5% v/v 2-mercaptoethanol) and subjected to
repeated freeze/boil cycles. Samples were separated using SDS–
PAGE and transferred to polyvinylidene fluoride (PVDF) mem-
branes. The following antibodies were used for probing: rabbit anti-
RIPK2 (4142S, Cell Signaling Technology), rabbit anti-RIPK2 (SC
22763, Santa Cruz), mouse anti-FLAG (F1804, Sigma), anti-b actin
(A-1978, Sigma), rabbit anti-p65 (631213, Upstate), rabbit anti-
phospho p65 (3033, Cell Signaling Technology), rabbit anti-phospho
p38 (9211, Cell Signaling Technology), mouse anti-phospho IjBɑ
(9246, Cell Signaling Technology), rabbit anti-IjBɑ (9242, Cell Sig-
naling Technology), mouse anti-ubiquitin (3936, Cell Signaling
Technology), rabbit anti-GAPDH (2118, Cell Signaling Technology),
human anti-K63-linked ubiquitin (Apu3.A8, Genentech), human
anti-M1-linked ubiquitin (1F11, Genentech), anti-K27-linked ubiqui-
tin (ab18153, abcam), goat anti-mouse Ig (1010-05), goat anti-rabbit
Ig (4010-05) and goat anti-rat Ig HRP (horseradish peroxidase, 3010-
05, Southern Biotech), and goat anti-human Ig (109-035-003, Jack-
son ImmunoResearch).
Cytokine measurement by ELISA
Cytokines from mouse serum or cell culture supernatant were mea-
sured by ELISA kits for IL-6, IL-8, TNF, and MCP-1, respectively
(Invitrogen), according to the manufacturer’s instructions. Sera and
supernatants were diluted 1:10 for MCP-1 measurements.
Immunoprecipitation of RIPK2 from mouse tissues
Organs from 6 weeks old wild-type C57BL/6 mice and FLAG-RIPK2
knock-in mice were lysed in IP buffer (150 mM NaCl, 50 mM Tris
pH 7.5, 10% glycerol, 1% Triton X-100, 2 mM EDTA, all from
SIGMA) supplemented with protease inhibitors (cOmplete protease
inhibitor cocktail, Roche) using a TissueLyser II (Qiagen). Samples
were clarified by centrifugation at 17,000 × g for 30 min, the pro-
tein concentration was assessed using a BCA assay (Thermo
Fisher) and 2 mg of protein per lysate were subjected to anti-FLAG
immunoprecipitation using 15 ul of packed magnetic anti-FLAG
beads (M2, Sigma) for 4 h. Beads were washed three times in IP
buffer, eluted with 2× SDS sample buffer, and subjected to
immunoblotting.
Ubiquitin enrichments (UBA, TUBE and pulldowns with K63- and
M1-specific ubiquitin antibodies)
20*106 THP-1 cells were treated with doxycycline (200 ng/ml) for
5 h and stimulated with L18-MDP (200 ng/ml, Invitrogen) for
30 min, washed in PBS, and lysed in 1–2 ml IP buffer (150 mM
NaCl, 50 mM Tris pH 7.5, 10% glycerol, 1% Triton X-100, 2 mM
EDTA) with protease and phosphatase inhibitors and 5 mM n-ethyl-
maleimide (NEM). Samples were clarified by centrifugation at
17,000 × g for 15 min and added directly to 20 ll packed glu-
tathione sepharose beads pre-bound with 100 lg GST-TUBE
(Ubiquillin-UBA4x) or GST-UBA (Ubiquillin-UBA1x) (Hjerpe et al,
2009). Beads were incubated on a rotating wheel at 4°C for at least
2 h, washed three times with IP buffer, and eluted with 2× SDS
sample buffer.
To enrich for K63- and M1-linked ubiquitin species, 20*106 THP-
1 cells were treated with doxycycline (200 ng/ml) for 5 h and stimu-
lated with L18-MDP (200 ng/ml, Invitrogen) for 30 min, washed
with PBS, and lysed in 1–2 ml IP buffer, as above, supplemented
with 6 M Urea (for anti-K63-linked ubiquitin pulldowns) or 8 M
Urea (for anti M1-linked ubiquitin pulldowns). Samples were clari-
fied by centrifugation at 17,000 × g for 15 min and 4 lg of anti-K63
or anti-M1-linked ubiquitin antibodies [Genentech; (Matsumoto
et al, 2012; Newton et al, 2008)] were added, followed by incuba-
tion on a rotating wheel at 4°C for at least 2 h. Antibodies were pre-
cipitated with 10 ll of equilibrated protein G agarose (Thermo),
washed three times in IP buffer without Urea, and eluted with
2× SDS sample buffer.
Two-step enrichment of modified RIPK2
Twelve dishes of confluent FLAG-RIPK2 BMDMs (equivalent of
approximately 25*107 cells or 25 mg of total protein) were primed
with IFNc (5 ng/ml) overnight and fresh IFNc was added the next
morning for another 2 h before stimulation with MDP (10 lg/ml)
for 30 min. Cells were harvested, washed in PBS, and lysed in 2 ml
IP buffer per dish (150 mM NaCl, 50 mM Tris pH 7.5, 10% glycerol,
1% Triton X-100, 2 mM EDTA; supplemented with protease and
phosphatase inhibitors and 5 mM n-ethylmaleimide (NEM)).
Lysates were clarified by centrifugation at 17,000 × g for 15 min,
and supernatants were directly added to 100 ll packed glutathione
sepharose beads pre-bound with 1 mg GST-UBA. Beads were incu-
bated on a rotating wheel at 4°C overnight, washed three times with
IP buffer, and eluted twice with two volumes of IP buffer supple-
mented with 20 mM reduced glutathione (pHed to 7.5). Elutions
were combined, diluted with an equal volume of IP buffer, and
added to 50 ll of packed magnetic anti-FLAG beads (M2, Sigma)
and incubated on a rotating wheel at 4°C for 4 h. Beads were
washed three times with IP buffer and eluted twice with two vol-
umes of 3x-FLAG peptide (1 mg/ml) in TBS pH 7.5.
BMDM diGly proteomics
For the two-step protocol in BMDMs, eluted protein material from
pulldowns of FLAG-RIPK2 expressing BMDMs was subjected to
tryptic digestion using the FASP method as previously described
(Wisniewski et al, 2009). Peptides were lyophilized using CentriVap
(Labconco) prior to reconstituting in 80 ll 0.1% FA/2% acetonitrile
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(ACN). Peptide mixtures were analyzed by nanoflow reversed-phase
liquid chromatography tandem mass spectrometry (LC-MS/MS) on
an M-Class HPLC (Waters) coupled to a Q Exactive Orbitrap mass
spectrometer (Thermo Fisher). Peptide mixtures were loaded in
buffer A (0.1% formic acid, 2% acetonitrile, Milli-Q water) and sep-
arated by reverse-phase chromatography using C18 fused silica
column (packed emitter, I.D. 75 lm, O.D. 360 lm × 25 cm length,
IonOpticks, Australia) using flow rates and data-dependent meth-
ods as previously described (Delconte et al, 2016; Kedzierski
et al, 2017).
THP-1 diGly proteomics
Frozen pellets from 50 × 106 WT THP-1 cells were lysed in 1%
sodium deoxycholate (SDC), 100 mM Tris–HCL pH 8.5, immediately
boiled for 5 min at 95°C and sonication for 30 s (Branson Soni-
fierer). Protein concentrations were estimated by tryptophan assay.
For protein reduction and alkylation, samples were incubated for
5 min at 45°C after addition of tris(2-carboxyethyl)phosphine
(TCEP) and 2-chloroacetamide (CAA) to a final concentration of
10 mM and 40 mM, respectively. Samples were digested using
trypsin (1:20 w/w, Sigma-Aldrich) in combination with LysC (1/100
w/w, Wako) at 37°C overnight. Protease activity was quenched by
addition of four-sample volumes 1% trifluoroacetic acid (TFA) in
isopropanol. Quenched samples were loaded onto SDB-RPS car-
tridges (StrataTM-X-C, 30 mg/3 ml, Phenomenex Inc), pre-equili-
brated with 4 ml 30% methanol (MeOH)/1% TFA, and washed
with 4 ml 0.2% TFA. After two washes with 4 ml 1%TFA in iso-
propanol and 1 wash with 0.2% TFA/2% acetonitrile (can), samples
were eluted twice with 2 ml 1.25% ammonium hydroxide(NH4OH)/
80% ACN. Eluted samples were diluted with ddH2O to a final ACN
concentration of 35%, snap frozen, and dried by lyophilization.
Lyophilized peptides were reconstituted in IAP buffer (50 mM
MOPS, pH 7.2, 10 mM Na2HPO4, 50 mM NaCl), and the peptide
concentration was estimated by tryptophan assay. For proteome
analysis, 10 lg of peptide material was taken and desalted on SDB-
RPS StageTips (Empore) (Kulak et al, 2014). Peptides were diluted
to a final volume of 200 ll with 0.2% TFA and loaded onto
StageTips, followed by a wash with 200 ll of 0.2% TFA and 200 ll
of 0.2%TFA/2%ACN, respectively. Captured peptides were
eluted with 60 ll of 1.25% Ammonium hydroxide(NH4OH)/80%
ACN and dried using a SpeedVac centrifuge (Eppendorf, Con-
centrator plus). Dried peptides were resuspended in buffer
A* (2% ACN/0.1% TFA).
K-ɛ-GG remnant containing peptides were enriched using the
PTMScan Ubiquitin Remnant Motif (K-ɛ-GG) Kit (Cell Signaling
Technology). Crosslinking of antibodies to beads and subsequent
immunopurification was performed with slight modifications as pre-
viously described (Udeshi et al, 2013). Briefly, cross-linked beads
were split equally into eight tubes (~ 31 lg of antibody per tube),
gently mixed with 1 mg peptide material (1 mg/ml) and incubated
for 1 h at 4°C. Beads were washed twice with cold IAP and five
times with cold ddH2O, and peptides were eluted twice with 50 ll
0.15% TFA. Eluted peptides were desalted and dried as described
above and resuspended in 5 ll buffer A* for LC/MS-MS analysis.
For the THP-1 diGly-enrichment analysis, samples were loaded
onto a 50 cm reversed-phase column [75 lm inner diameter, packed
in house with ReproSil-Pur C18-AQ 1.9 lm resin (Dr. Maisch
GmbH)]. The column temperature was maintained at 60°C using a
homemade column oven. Peptides were separated with a binary
buffer system of buffer A (0.1% formic acid (FA)) and buffer B
(80% acetonitrile plus 0.1% FA), at a flow rate of 300 nl/min. Nano
flow Liquid chromatography was performed with an EASY-nLC
1200 system (Thermo Fisher Scientific), which was directly coupled
online with the mass spectrometer (Q Exactive HF-X, Thermo Fisher
Scientific) via a nano-electrospray source. For proteome measure-
ments, 500 ng were loaded and eluted with a gradient starting at
5% buffer B and stepwise increased to 30% in 95 min, 60% in
5 min, and 95% in 5 min. The mass spectrometer was operated in
Top15 data-dependent mode (DDA) with a full scan range of 300–
1,650 m/z at 60,000 resolution with an automatic gain control
(AGC) target of 3e6 and a maximum fill time of 20 ms. Precursor
ions were isolated with a width of 1.4 m/z and fragmented by
higher-energy collisional dissociation (HCD) (NCE 27%). Fragment
scans were performed at a resolution of 15,000, an AGC of 1e5, and
a maximum injection time of 28 ms. Dynamic exclusion was
enabled and set to 30 s.
For K-ɛ-GG peptide samples, 2 ll were loaded and eluted with a
gradient starting at 3% buffer B and stepwise increased to 7% in
6 min, 20% in 49 min, 36% in 39 min, 45% in 10 min, and 95% in
4 min. The mass spectrometer was operated in Top12 data-depen-
dent mode (DDA) with a full scan range of 250–1,350 m/z at 60,000
resolution with an automatic gain control (AGC) target of 3e6 and a
maximum fill time of 20 ms. Precursor ions were isolated with a
width of 1.4 m/z and fragmented by higher-energy collisional disso-
ciation (HCD) (NCE 28%). Fragment scans were performed at a res-
olution of 30,000, an AGC of 1e5 and a maximum injection time of
110 ms. Dynamic exclusion was enabled and set to 15 s.
MS data processing
For BMDM data sets, raw files consisting of high-resolution MS/MS
spectra were processed with MaxQuant (version 1.5.8.3) for feature
detection and protein identification using the Andromeda search
engine (Cox et al, 2011). Extracted peak lists were searched against
the UniProtKB/Swiss-Prot Mus musculus database (October 2016)
and a separate reverse decoy database to empirically assess the false
discovery rate (FDR) using strict trypsin specificity allowing up to
two missed cleavages. The minimum required peptide length was
set to seven amino acids. The mass tolerance for precursor ions and
fragment ions were 20 ppm and 0.5 Da, respectively. The search
included variable modifications of oxidation (methionine), amino-
terminal acetylation, carbamidomethyl (cysteine), GlyGly or ubiqui-
tination (lysine), phosphorylation (serine, threonine, or tyrosine),
and N-ethylmaleimide (cysteine). Raw MS data were also searched
with PEAKS, version 8 (Bioinformatics Solutions) using a Swiss-Prot
Human database and the same variable and fixed modifications as
described above. A 0.1% and 1% FDR cutoff were applied at the
PSM and peptide/protein levels, respectively.
Raw MS data from THP-1 cells were searched against the UniProt
Human FASTA (21,051 sequences) using MaxQuant (version
1.6.2.10) with a 1% FDR at peptide and protein levels. The match
and alignment time window for the match between run (MBR) algo-
rithm were set to 0.7 min and 20 min, respectively. A ratio count of
two was used for the MaxLFQ algorithm. Cysteine carbamidomethy-
lation was defined as fixed, protein N-terminal acetylation and
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methionine oxidation as variable modification. In case of K-ɛ-GG
samples, “GlyGly (K)” was additionally selected as variable modifi-
cations. Enzyme specificity was set to trypsin and two missed cleav-
ages were allowed, while permitting a maximum of five
modifications per peptide.
Molecular modeling
The effects of K209R, I212D, and I212A mutations on the structural
integrity were modeled using the DynaMut software (Rodrigues et al,
2018) using the kinase domain of RIPK2 (PDB: 4C8B) as the input.
Recombinant protein purification
pGEX-6 P-1 or pGEX-6 P-3 plasmids encoding XIAP-BIR2, Ubiquillin-
UBA1x (UBA), or Ubiquillin-UBA4x (TUBE; Hjerpe et al, 2009) were
transformed into BL21 (DE3þ) bacteria and grown in Super broth
overnight at 37°C. Overnight culture was diluted 1:10 and grown
until OD595 was 0.8. Isopropylthiogalactoside (IPTG) (0.3 mM) was
added for 4 h at 30°C. Cells were pelleted and resuspended in Buffer
A (50 mM Tris pH 8.0, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 10%
glycerol, all from SIGMA) and sonicated. After centrifugation at
21,000 g for 30 min, the supernatant was incubated with glu-
tathione sepharose4B (GE Healthcare) for 4 h, washed five times
with Buffer A, and eluted 2 × 45 min with 10 mM reduced glu-
tathione in Buffer A at 4°C.
Generation of doxycycline-inducible cell lines
Sequences of full length hsRIPK2 with an N-terminal 3x-Flag tag were
synthesized by Genscript and cloned into doxycycline-inducible len-
tiviral expression vectors (pF_TRE3G_rtTAAd_puro (Takara Bio)).
For lentiviral transfections, 2.5 lg of the plasmid of choice was trans-
fected into HEK293T cells together with 1 lg pVSV-G and 1.5 lg
pCMVDR8.2 using an Effectene transfection kit (Qiagen). Twenty-
four hours after transfection, the media was changed and virus was
harvested after another 24 h. Media was filtered and supplemented
with polybrene (4 lg/ml). Viral media was then applied to cell lines,
centrifuged for 45 min at 1,000 g at 30°C. After 2 days of incubation,
cells were selected using 2.5 lg/ml puromycin (Sigma).
Thermal shift assay
5*106 THP-1 cells were treated with doxycycline (200 ng/ml, Sigma)
for 5 h, washed in PBS, and resuspended in PBS supplemented with
protease inhibitors. Cell suspensions were transferred into PCR
tubes and incubated for 3 min at a temperature gradient (37–60°C)
in a PCR machine. Samples were cooled to room temperature, lysed
by repeated freeze-thawing, and centrifuged at 20,000 g for 20 min
at 4°C. Supernatants were harvested and 2× SDS sample buffer was
added, before analysis by Western blot.
XIAP-BIR2 binding assay
20*106 THP-1 cells were treated with doxycycline (200 ng/ml, Sigma)
for 5 h, washed in PBS, and lysed in 1–2 ml IP buffer (150 mM NaCl,
50 mM Tris pH 7.5, 10% glycerol, 1% Triton X-100, 2 mM EDTA) with
cOmplete protease inhibitor cocktail, Roche, and phosphatase
inhibitors (5 mM b-Glycerophosphate, 1 mM Sodium molybdate,
2 mM Sodium pyrophosphate, 10 mM Sodium fluoride) and 5 mM n-
ethylmaleimide (NEM, Sigma). Lysates were clarified by centrifugation
at 17,000 × g for 15 min and added directly to 20 ll packed glutathione
sepharose beads pre-bound with 100 lg GST-XIAP-BIR2. Beads were
incubated on a rotating wheel at 4°C for at least 2 h, washed three
times with IP buffer, and eluted with 2× SDS sample buffer.
Statistical analysis
The P values were calculated using two-way ANOVA using Prism
v.8 (GraphPad). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and
****P ≤ 0.0001; P values > 0.05 are indicated as not significant
(ns). Normal distribution was confirmed using the D’Agostino–Pear-
son test (Fig 3B), respectively, the Shapiro–Wilk test (Fig 4D) using
GraphPad PRISM software.
Data availability
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository
(Perez-Riverol et al, 2019) with the dataset identifier PXD017741
(http://www.ebi.ac.uk/pride/archive/projects/PXD017741).
Expanded View for this article is available online.
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